Literature DB >> 350229

Collagen in the cellular and fibrotic stages of scleroderma.

R Fleischmajer, S Gay, W N Meigel, J S Perlish.   

Abstract

The collagen in localized and systemic scleroderma skin was studied by light microscopy with silver impregnation (50 patients), electron microscopy (14 patients), and immunofluorescence microscopy using specific antibodies against Type I and Type III collagens (12 patients). In the cellular stage, the dermis and adipose tissue revealed perivascular or diffuse cellular infiltrates (mostly lymphocytes, plasma cells, and macrophages), accompanied by deposition of Type III collagen. The lower dermis also showed an increase in Type III collagen. In the fibrotic stage, the papillary layer showed a reduction and/or clumping of Type III collagen as compared to normal skin. The lower dermis and the adipose tissue revealed compact collagen consisting exclusively of Type I collagen or a mixture of Type I and Type III collagen. The pattern of Type III collagen distribution was similar to that of reticulin, thus suggesting that at least some reticulin fibrils may represent Type III collagen.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350229     DOI: 10.1002/art.1780210404

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

Review 1.  Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis.

Authors:  B Eckes; D Kessler; M Aumailley; T Krieg
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

3.  Immunochemical analysis of human kidney reticulin.

Authors:  R Fleischmajer; L Jacobs; J S Perlish; B Katchen; E Schwartz; R Timpl
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

4.  Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis.

Authors:  N G Guseva; N V Anikina; R Myllylä; L Risteli; J Risteli; J V Chochlova; K I Kivirikko; V A Nassonova
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

5.  Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (alpha 1-3)-galactose epitopes.

Authors:  A Gabrielli; M Candela; A M Ricciatti; M L Caniglia; J Wieslander
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

6.  Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis.

Authors:  Remedios Castello-Cros; Diana Whitaker-Menezes; Alex Molchansky; George Purkins; Louis J Soslowsky; David P Beason; Federica Sotgia; Renato V Iozzo; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

Review 7.  Matrix remodeling in systemic sclerosis.

Authors:  Andrew Leask
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

8.  Enhanced production of transforming growth factor-beta (TGF-beta) during autologous mixed lymphocyte reaction of systemic sclerosis patients.

Authors:  H Ota; S Kumagai; A Morinobu; H Yanagida; K Nakao
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Coordinated regulation of type I and type III collagen production and mRNA levels of pro alpha 1(I) and pro alpha 2(I) collagen in cultured morphea fibroblasts.

Authors:  T Vuorio; J K Mäkelä; V M Kähäri; E Vuorio
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

10.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.

Authors:  Masahide Kubo; Joanna Czuwara-Ladykowska; Omar Moussa; Margaret Markiewicz; Edwin Smith; Richard M Silver; Stefania Jablonska; Maria Blaszczyk; Dennis K Watson; Maria Trojanowska
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.